🇺🇸 FDA
Patent

US 10668062

Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes

granted A61KA61K31/34A61K31/4178

Quick answer

US patent 10668062 (Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes) held by Lixte Biotechnology, Inc. expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Lixte Biotechnology, Inc.
Grant date
Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/34, A61K31/4178, A61K31/4525, A61K31/496